Released May 9, 2025, before the open
10-Q filed May 9, 2025, 39 days after period end · 0001558370-25-007063
Q1 2025 · 10-Q
Revenue$10.11M$10.11M +169.8% vs Q1 2024−44.5% vs Q4 2024
Net Income-$3.62M-$3.62M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.05-$0.05 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$4,145,000N/M
Operating Cash Flow-$5,058,000N/M
Free Cash Flowderived-$5,364,000N/M
Margins · derived
Operating margin-41.0%+88.6 pt vs Q1 2024
Net margin-35.8%+86.8 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $10.11M | $3.75M | $9.59M | $16.09M |
| Net Income | -$3.62M | -$4.60M | -$3.13M | -$2.29M |
| EPS Diluted | -$0.05 | -$0.06 | -$0.05 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR